

Forthcoming Papers in ANTICANCER RESEARCH [ISSN (print): 0250-7005; ISSN (online): 1791-7530]**Special Issue on New Anticancer Agents**

Pediatric Patients with Refractory Central Nervous System Tumors: Experiences of a Clinical Trial Combining Bevacizumab and Temozolomide. S.A. PIHA-PAUL, S.J. SHIN, T. VATS, N. GUHA-THAKURTA, J. AARON, M. RYTTING, E. KLEINERMAN, R. KURZROCK (*Houston, TX; La Jolla, CA, USA*)

Synergistic Inhibition of HCC and Liver Cancer Stem Cell Proliferation by Targeting RAS/RAF/MAPK and WNT/ β -Catenin Pathways. R. GALUPPO, E. MAYNARD, M. SHAH, M.F. DAILY, C. CHEN, B.T. SPEAR, R. GEDALY (*Lexington, KY, USA*)

Cytotoxic Activity of N,N'-Bis (2-hydroxybenzyl) Ethylenediamine Derivatives in Human Cancer Cell Lines. M.A. MUSA, V.L.D. BADISA, L.M. LATINWO (*Tallahassee, FL, USA*)

Mechanisms by which Synthetic 6,7-Annulated-4-substituted Indole Compounds with Antiproliferative Activity Disrupt Mitosis and Block Cytokinesis in Human HL-60 Tumor Cells In Vitro. J.-P. H. PERCHELLET, E.M. PERCHELLET, C.R. SINGH, M.T. MONNETT, E.R. STUDER, P.D. THORNTON, N. BROWN, D. HILL, B. NEUENSWANDER, G.H. LUSHINGTON, C. SANTINI, K.R. BUSZEK (*Manhattan; Lawrence, KS; Kansas City, MO, USA*)

Family of Peptides Synthesized in the Human Body Have Anticancer Effects. D.L. VESELY (*Tampa, FL, USA*)

Inhibitory Effect of Orally Administered Sulfated Polysaccharide Ascophyllan Isolated from *Ascophyllum nodosum* on the Growth of Sarcoma-180 Solid Tumor in Mice. Z. JIANG, R. ABU, S. ISAKA, S. NAKAZONO, M. UENO, T. OKIMURA, K. YAMAGUCHI, T. ODA (*Nagasaki; Yamaguchi, Japan*)

Synthesis and Antitumour Activity of a New Trinuclear Platinum Compound [$\text{cis-PtCl}(\text{NH}_3)_2\mu\{\text{trans-Pt}(3\text{-hydroxypyridine})_2\text{H}_2\text{N}(\text{CH}_2)_5\text{NH}_2\}_2$] Cl_4 in Human Ovarian Cancer Cells. S.A. HAMAD, P. BEALE, J.Q. YU, F. HUQ (*Sydney, NSW, Australia*)

COX2 Inhibitor NS398 Reduces HT-29 Cell Invasiveness Modulating Signalling Pathways Mediated by EGFR and HIF1- α . C. BOCCA, F. BOZZO, A. MIGLIETTA (*Torino, Italy*)

Impact of Combination Chemotherapy with Itraconazole on Survival for Patients with Recurrent or Persistent Ovarian Clear Cell Carcinoma. H. TSUBAMOTO, T. SONODA, M. YAMASAKI, K. INOUE (*Hyogo; Kobe, Japan*)

Effect of Co-administration of Ketoconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics, Safety and Tolerability of Navitoclax, A First-in-class Oral Bcl-2 Family Inhibitor, in Cancer Patients. S.H. AHMED, J. YANG, A. GRAHAM, A. PATNAIK, K. HOLEN, R. PRADHAN, H. XIONG (*North Chicago, IL; San Antonio, TX; Cheshire, CT, USA; Cairo, Egypt*)

Quantitative Structure-Activity Relationship Analysis of Cytotoxicity and Anti-UV Activity of 2-Aminotropones. S. SEKINE, C. SHIMODAIRA, Y. UESAWA, H. KAGAYA, Y. KANDA, M. ISHIHARA, O. AMANO, H. SAKAGAMI, H. WAKABAYASHI (*Sakado, Saitama; Tokyo, Japan*)

Multidrug Resistance Reversing Activity of Newly Developed Phenothiazines on P glycoprotein (ABCB1)-related Resistance of Mouse T-Lymphoma Cells. G. SPENGLER, D. TAKÁCS, Á. HORVÁTH, Z. RIEDL, G. HAJÓS, L. AMARAL, J. MOLNÁR (*Szeged; Budapest, Hungary; Lisbon, Portugal*)

Sodium Butyrate, a Histone Deacetylase Inhibitor, Regulates Lymphangiogenic Factors in Oral Cancer Cell Line HSC-3. T. YAMAMURA, N. MATSUMOTO, Y. MATSUE, M. OKUDERA, Y. NISHIKAWA, Y. ABIKO, K. KOMIYAMA (*Tokyo; Chiba, Japan*)

Targeted Treatment of Ovarian Cancer - The Multiple - Kinase - Inhibitor Sorafenib As a Potential Option. E. SMOLLE, V. TAUCHER, E. PETRU, J. HAYBAECK (*Graz, Austria*)

Piperine Enhances the Efficacy of TRAIL-based Therapy for Triple-negative Breast Cancer Cells. S. ABDELHAMED, S. YOKOYAMA, A. REFAAT, K. OGURA, H. YAGITA, S. AWALE, I. SAIKI (*Toyama; Tokyo, Japan*)

Translymphatic Chemotherapy Targeting Sentinel Lymph Nodes Using a Novel Phospholipid Polymer–Paclitaxel Conjugate. T. OYAMA, H. TAKEUCHI, S. MATSUDA, S. OZAWA, M. KITAJIMA, Y. KITAGAWA (*Tokyo; Isehara, Kanagawa; Otawara, Tochigi, Japan*)

Novel Ruthenium – Gamma-linolenic Acid Complex Inhibits C6 Rat Glioma Cell Proliferation *In Vitro* and in the Orthotopic C6 Model *In Vivo* After Osmotic Pump Infusion. J.A. MIYAKE, M. BENADIBA, G. RIBEIRO, D. DE OLIVEIRA SILVA, A. COLQUHOUN (*São Paulo, SP, Brazil*)

Antiproliferative and Apoptosis-inducing Activity of Nobiletin Against Three Subtypes of Human Breast Cancer Cell Lines. C. CHEN, M. ONO, M. TAKESHIMA, S. NAKANO (*Fukuoka, Japan*)

Anticancer Activity of Novel pyrido[2,3-b]indolizine Derivatives: The Relevance of Phenolic Substituents. A. BOOT, A. BRITO, T. VAN WEZEL, H. MORREAU, M. COSTA, F. PROENÇA (*Leiden, Netherlands; Braga, Portugal*)

Evaluation of Radioprotective Effect of Pilocarpine Ingestion on Salivary Glands. M.J. PIMENTEL, M.M. BATISTA FILHO, M. ARAÚJO, D.Q. GOMES, L.J. DA COSTA (*Piracicaba-SP; Joao Pessoa-PB; Campina Grande-PB, Brazil*)

Metformin Suppresses Sonic Hedgehog Expression in Pancreatic Cancer Cells. M. NAKAMURA, A. OGO, M. YAMAMURA, Y. YAMAGUCHI, H. NAKASHIMA (*Kurashiki, Japan*)

A Pilot Study of Cisplatin and Etoposide With and Without Radiotherapy for Advanced Malignant Thymoma. A. TAMIYA, A. MATSUMURA, T. TSUJI, M. MORIMOTO, K. ASAMI, K. OKISHIO, S. SHIMIZU, H.-E. YOON, S. ATAGI, M. AKIRA, M. KITAICHI, T. KAWAGUCHI (*Sakai, Osaka, Japan*)

Comparison of Common Terminology Criteria for Adverse Events v3.0 and Radiation Therapy Oncology Group Toxicity Score System After High-dose-rate Interstitial Brachytherapy as Monotherapy for Prostate Cancer. K. YOSHIDA, H. YAMAZAKI, S. NAKAMARA, K. MASUI, T. KOTSUMA, H. AKIYAMA, E. TANAKA, Y. YOSHIOKA (*Takatsuki; Osaka; Suita, Osaka; Kyoto, Japan*)

Combinatorial Effects of PARP Inhibitor PJ34 and Histone Deacetylase Inhibitor Vorinostat on Leukemia Cell Lines. E. JASEK, M. GAJDA, G.J. LIS, M. JASIŃSKA, J.A. LITWIN (*Krakow, Poland*)

Subcutaneous Administration of Anticancer Agents. D. LEVEQUE (*Strasbourg, France*)

New Treatment Paradigm for Patients With Anaplastic Oligodendroglial Tumors. J. POLIVKA, JR, J. POLIVKA, V. ROHAN, O. TOPOLCAN (*Plzen, Czech Republic*)

Uptake and Efflux of Rhenium in Cells Exposed to Rhenium Diseleno-ether and Tissue Distribution of Rhenium and Selenium After a Rhenium Diseleno-ether Treatment in Mice. P. COLLERY, G. BASTIAN, F. SANTONI, A. MOHSEN, M. WEI, T. COLLERY, A. TOMAS, D. DESMAELE, J. D'ANGELO (*Algajola; Paria; Bastia, France*)

Targeting Extracellular ROS Signalling of Tumor Cells. G. BAUER (*Freiburg, Germany*)

Molecular Basis of 5-Fluorouracil-related Toxicity; Lessons from Clinical Practice. P. PAPANASTASOPOULOS, J. STEBBING (*London, UK*)

Pertuzumab: Development Beyond Breast Cancer. P. BARTHÉLÉMY, J. LEBLANC, V. GOLDBARG, F. WENDLING, J.-E. KURTZ (*Strasbourg, France*)

New Developments in the Treatment of Metastatic Melanoma: Immune Checkpoint Inhibitors and Targeted Therapies. K. AZIJLI, E. STELLOO, G.J. PETERS, A.J.M. VAN DEN EERTWEGH (*Amsterdam, the Netherlands*)

Impact of S100A8 Expression on Kidney Cancer Progression and Molecular Docking Studies for Kidney Cancer Therapeutics. Z. MIRZA, H.-J. SCHULTEN, H.M. FARSI, J.A. AL-MAGHRABI, M.A. GARI, A.G. CHAUDHARY, A.M. ABUZENADAH, M.H. AL-QAHTANI, S. KARIM (*Jeddah, Saudi Arabia*)

The Role of Prophylactic Hyperthermic Intraperitoneal Chemotherapy in the Management of Serosal Involved Gastric Cancer. E. SALADINO, F. FLERES, C. MAZZEO, V. PRUITI, M. SCOLLICA, M. ROSSITTO, E. CUCINOTTA, A. MACRÌ (*Messina, Italy*)

Full-dose of Cisplatin and Oral Vinorelbine Concomitant with Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: A Multicenter Phase II Study. Ó. JUAN, A. SÁNCHEZ-HERNÁNDEZ, S. VÁZQUEZ, J. CASAL, J.L. FIRVIDA, F. APARISI, J. MUÑOZ, J. GARCÍA-SÁNCHEZ, R. GIRONÉS, M. LÁZARO, V. GINER (*Valencia; Castellón; Lugo; Vigo; Alcoy; Xativa; Sagunto, Spain*)

Curcumin Suppresses Vasculogenic Mimicry Capacity of Hepatocellular Carcinoma Cells through STAT3 and PI3K/AKT Inhibition. K. CHIABLAEM, K. LIRDPRAPAMONGKOL, S. KEERATICHAMROEN, R. SURARIT, J. SVASTI (*Bangkok, Thailand*)

Silibinin Downregulates the Expression of Secreted Phospholipase A2 Enzymes in Cancer Cells. A. HAGELGANS, B. NACKE, M. ZAMARAEVA, G. SIEGERT, M. MENSCHIKOWSKI (*Dresden, Germany; Bialystok, Poland*)

Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. E. SMOLLE, V. TAUCHER, J. HAYBAECK (*Graz, Austria*)

Effects of Angiotensin, Vasopressin and Aldosterone on Proliferation of MCF-7 Cells and Their Sensitivity to Doxorubicin. J.M. DELOU, A.G. LOPES, M.A. CAPELLA (*Rio de Janeiro, RJ, Brazil*)

Enhanced Efficacy of CKD-516 in Combination with Doxorubicin: Preclinical Evaluation Using a Hepatocellular Carcinoma Xenograft Model. Y.I. KIM, K.W. KIM, H.K. LEE, J. PARK, J.W. CHUNG, H. YOUN, S.J. KIM, D.-H. KIM, J.-C. TSENG, J.M. LEE (*Seoul, Republic of Korea; Boston, MA, USA*)

The Addition of a Pregnenolone Pendant Group Enhances the Anticancer Properties of Titanocene Dichloride in a MCF-7 Xenograft Model. G. RAMOS, Y. LOPERENA, G. ORTIZ, F. REYES, A. SZETO, J. VERA, J. VELEZ, J. MORALES, D. MORRERO, L. CASTILLO, S. DHARMAWARDHANE, E. MELENDEZ, A.V. WASHINGTON (*San Juan Puerto Rico, Puerto Rico*)

The Influence of Treatment with Retinoic Acid and Thalidomide on the Radiosensitivity of U343 Glioblastoma Cells. D. MILANOVIĆ, P. MAIER, D.H. SCHANNE, F. WENZ, C. HERSKIND (*Heidelberg; Freiburg, Germany*)

Dipalmitoleoyl-phosphatidylethanolamine Induces Apoptosis of NCI-H28 Malignant Mesothelioma Cells. Y. KAKU, A. TSUCHIYA, T. KANNO, T. NISHIZAKI (*Nishinomiya, Japan*)

Ascorbic Acid Induces either Differentiation or Apoptosis in MG-63 Osteosarcoma Lineage. M.T. VALENTI, M. ZANATTA, L. DONATELLI, G. VIVIANO, C. CAVALLINI, M.T. SCUPOLI, L. DALLE CARBONARE (*Verona, Italy*)

A Monastrol-derived Compound, LaSOM 63, Inhibits Ecto-5'Nucleotidase/CD73 Activity and Induces Apoptotic Cell Death of Glioma Cell Line. F. FIGUEIRO, F.B. MENDES, P.F. CORBELINI, F. JANARELLI, E.H. JANDREY, D. RUSSOWSKY, V.L. EIFLER-LIMA, A.M. BATTASTINI (*Porto Alegre, Rio Grande do Sul, Brazil*)

Induction of Apoptosis by Deinoxanthin in Human Cancer Cells. Y.-J. CHOI, J.-M. HUR, S. LIM, M. JO, D.H. KIM, J.-I. CHOI (*Jeongeup; Gwangju, South Korea*)

Potent Reactive Oxygen Species-JNK-p38 Activation by Sodium Salicylate Potentiates Death of Primary Effusion Lymphoma Cells. K. VAETEEWOOTTACHARN, M. MITCHAI, P. SRIKON, S. HATTORI, R. KARIYA, K. MATSUDA, S. WONGKHAM, S. OKADA (*Kumamoto, Japan; Khon Kean, Thailand*)

Behavior-selective Apoptotic Capacity of 4-(3,4,5-Trimethoxyphenoxy) Benzoic Acid and Its Methyl Derivative on Two Breast Cancer Cell Lines. K.-H. LEE, W.-Y. HO, S.-J. WU, T.-L. CHENG, P.-J. HUANG, C.C.C. WANG, J.-H. HUNG (*Tainan; Kaohsiung, Taiwan, ROC; Los Angeles, CA, USA*)

Radiosensitizing Effect of Rosmarinic Acid in Metastatic Melanoma B16F10 Cells. M. ALCARAZ, M. ALCARAZ-SAURA, D.G. ACHEL, A. OLIVARES, J.A. LOPEZ-MORATA, J. CASTILLO (*Espinardo, Murcia, Spain; Legon-Accra, Ghana*)

Quercetin-3-O-glucoside Induces Human DNA Topoisomerase II Inhibition, Cell Cycle Arrest and Apoptosis in Hepatocellular Carcinoma Cells. S. SUDAN, H.P. RUPASINGHE (*Truro, NS, Canada*)

3,3',4',5'-Tetramethoxychalcone Inhibits Human Oral Cancer Cell Proliferation and Migration via p53-mediated Mitochondrial-Dependent Apoptosis. C.-K. LAI, Y. KOTESWARA RAO, K.-R. CHANG, C.-W. LIN, H.-L. SU, C.-S. CHANG, C.-H. LAI, Y.-M. TZENG (*Taichung, Taiwan, ROC*)

Cytarabine-resistant Leukemic Cells Are Moderately Sensitive to Clofarabine In Vitro. T. YAMAUCHI, K. UZUI, R. NISHI, H. SHIGEMI, T. UEDA (*Fukui, Japan*)

Targeting Tropomyosin-Receptor Kinase Fused Gene in Cancers. Y. CHEN, S.-H. TSENG (*New Taipei; Taoyuan; Taipei, Taiwan, ROC*)

Phase I Study of Combination Therapy with Irinotecan, Leucovorin, and Bolus and Continuous-infusion 5-Fluorouracil (FOLFIRI) for Advanced Colorectal Cancer in Japanese Patients. Y. SASAKI, T. HAMAGUCHI, T. ARAI, A. GOTO, T. URA, K. MURO, Y. YAMADA, K. SHIRAO, Y. SHIMADA (*Tokyo, Japan*)

Analysis of Adverse Events of Bevacizumab-containing Systemic Chemotherapy for Metastatic Colorectal Cancer in Japan. T. ISOBE, K. UCHINO, C. MAKIYAMA, H. ARIYAMA, S. ARITA, S. TAMURA, M. KOMODA, H. KUSABA, T. SHIRAKAWA, T. ESAKI, K. MITSUGI, S. TAKAISHI, K. AKASHI, E. BABA (*Fukuoka, Japan*)

New Anticancer Agents: Role of Clinical Pharmacy Services. D. LEVEQUE, A. DELPEUCH, B. GOURIEUX (*Strasbourg, France*)

An Activation of AXL and Antitumor Effects of Anti-AXL Monoclonal Antibody in Lung Adenocarcinoma. S. IIDA, Y. MIKI, T. SUZUKI, K. MORI, M. SAITO, H. NIIKAWA, T. KONDO, H. YAMADA-OKABE, H. SASANO (*Sendai, Miyagi; Gotemba, Shizuoka, Japan*)

Oncological Outcomes of Hormonal Therapy with a Gonadotropin-releasing Hormone Agonist Combined with a Steroidal or Non-steroidal Antiandrogen in Prostate Cancer Patients. T. IGAWA, T. TSURUSAKI, K. NOMATA, M. HAYASHI, M. FURUKAWA, H. SAKAI (*Nagasaki; Omura; Sasebo, Japan*)

The Use of Bevacizumab in Non-small Cell Lung Cancer (NSCLC): An Update. S. LAURO, C.E. ONESTI, R. RIGHINI, P. MARCHETTI (*Rome, Italy*)

A Facile One Pot Synthesis and Anticancer Evaluation of Novel Substituted 1,2-dihydropyridine and 1,2,3,4-tetrahydropyrimidine Analogues. A. BARI, A. KHAN, M.K. PARVEZ, A.M. ALANAZI, S.S. ALI, M.S. AL-DOSARI, A.M. ALOBAID (*Riyadh, Saudi Arabia*)

Special Issue on Breast Cancer

Clinical Utility of Ultrasound-Needle Biopsy for Preoperative Staging of the Axilla in Invasive Breast Cancer. N. HOUSSAMI, S. CE DIEPSTRATEN, H.S. CODY III, R.M. TURNER, A.R. SEVER (*Sydney, NSW, Australia; Utrecht, Netherland; New York, NY, USA*)

Mapping Oxidative Changes in Breast Cancer: Understanding the Basic to Reach the Clinics. A. MENCALHA, V.J. VICTORINO, R. CECCHINI, C. PANIS (*Rio de Janeiro; São Paulo; Londrina, Brazil*)

Morphometric and Fractal Dimension Analysis Identifies Early Neoplastic Changes in Mammary Epithelium of MMTV-cNeu Mice. J.W. FUSELER, J.P. ROBICHAUX, H.I. ATIYAH, A.F. RAMSDELL (*Columbia; Charleston, SC, USA*)

Human Chorionic Gonadotropin Suppresses Human Breast Cancer Cell Growth Directly via p53-mediated Mitochondrial Apoptotic Pathway and Indirectly via Ovarian Steroid Secretion. T. YURI, Y. KINOSHITA, Y. EMOTO, K. YOSHIZAWA, A. TSUBURA (*Hirakata, Osaka, Japan*)

Risk Factors Pathological and Phenotypic Features of Male Breast Cancer in Greece. N. TSOUKALAS, E. MOIROGIORGOU, M. TOLIA, N. PISTAMALTZIAN, E. BOURNAKIS, K. PAPADIMITRIOU, S. DEMIRI, C. PANOPOULOS, G. KOUMAKIS, A. EFREMIDIS, HELLENIC SOCIETY FOR THE STUDY OF BREAST CANCER (HES-BRECA) (*Athens, Greece; New York, NY, USA*)

Adjuvant Chemotherapy in Node-negative Breast Cancer: UPA/PAI-1 Determinations for 163 Cases. L. VÉNAT-BOUVET, V. FERMEAUX, S. LEOBON, N. SAIDI, J. MONTEIL, J. MOLLARD, Y. AUBARD, I. JAMMET, N. TUBIANA-MATHIEU (*Limoges, France*)

Endothelial Dysfunction as a Determinant of Trastuzumab-mediated Cardiotoxicity in Patients with Breast Cancer. A. SANDOO, G.D. KITAS, A.R. CARMICHAEL (*Dudley, West Midlands, UK*)

Accuracy of Mammography, Digital Breast Tomosynthesis, Ultrasound and MR Imaging in Preoperative Assessment of Breast Cancer. G. MARISCOTTI, N. HOUSSAMI, M. DURANDO, L. BERGAMASCO, P.P. CAMPANINO, C. RUGGIERI, E. REGINI, A. LUPARIA, R. BUSSONE, A. SAPINO, P. FONIO, G. GANDINI (*Turin, Italy; Sydney, NSW, Australia; Brussels, Belgium*)

The Management of Screen-detected Breast Cancer. M. AHMED, M. DOUEK (*London, UK*)

Meta-analysis of Vitamin D Sufficiency for Improving the Survival of Patients with Breast Cancer. S.B. MOHR, E.D. GORHAM, J. KIM, H. HOFFLICH, C.F. GARLAND (*San Diego; La Jolla, CA, USA*)

Characteristics Associated with Upgrading to Invasiveness After Surgery of a DCIS Diagnosed Using Percutaneous Biopsy. J.-C. HOGUE, L. MORAIS, L. PROVENCHER, C. DESBIENS, B. POIRIER, É. POIRIER, S. JACOB, C. DIORIO (*Quebec City, QC, Canada*)

Co-expression of Stem Cell Markers ALDH1 and CD44 in Non-malignant and Neoplastic Lesions of the Breast. A. DA CRUZ PAULA, O. MARQUES, A.M. ROSA, M. DE FÁTIMA FARIA, A. RÊMA, C. LOPES (*Porto, Portugal*)

Current Approaches to Managing Partial Breast Defects: The Role of Conservative Breast Surgery Reconstruction. A. MENDONÇA MUNHOZ, E. MONTAG, J.R. FILASSI, R. GEMPERLI (*São Paulo, Brazil*)

Expression of Matrix Metalloproteinases (MMPs) in Primary Human Breast Cancer: MMP-9 as a Potential Biomarker for Cancer Invasion and Metastasis. A. MERDAD, S. KARIM, H.-J. SCHULTEN, A. DALLOL, A. BUHMEIDA, F. AL-THUBAITY, M.A. GARI, A.G. CHAUDHARY, A.M. ABUZENADAH, M.H. AL-QAHTANI (*Jeddah, Saudi Arabia*)

Genetic and Epigenetic Aspects of Breast Cancer Progression and Therapy. S. BYLER, S. GOLDGAR, S. HEERBOTH, M. LEARY, G. HOUSMAN, K. MOULTON, S. SARKAR (*Boston, MA, USA*)

T1-T2 Breast Cancers with Nodal Metastasis: Characteristics of pN2 or Higher Disease Compared with pN1 Disease. M.Y. KIM, N. CHOI, J.-H. YANG, Y.B. YOO, K.S. PARK, W.S. KIM (*Seoul, South Korea*)

Cell Identity Disruption in Breast Cancer Precursors. D. CORADINI, P. BORACCHI, S. ORIANA, E. BIGANZOLI, F. AMBROGI (*Milan, Italy*)

QoL of Recently Treated Patients with Breast Cancer Improves Spontaneously, as Well as by Participating in Exercise Intervention Study. H. PENTTINEN, M. RAUTALIN, R. ROINE, T. JAHKOLA, P.-L. KELLOKUMPU-LEHTINEN, R. HUOVINEN, H. KAUTIAINEN, S. JÄRVENPÄÄ, L. HAKAMIES-BLOMQVIST, C. BLOMQVIST, T. SAARTO (*Helsinki; Turku; Jyväskylä; Äänekoski, Finland*)

Plasma Plasminogen Activator Inhibitor-1 (PAI-1) Levels in Breast Cancer – Relationship to Clinical Outcome. P. FERRONI, M. ROSELLI, I. PORTARENA, V. FORMICA, S. RIONDINO, F. LA FARINA, L. COSTARELLI, A. MELINO, G. MASSIMIANI, F. CAVALIERE, R. PALMIROTTA, F. GUADAGNI (*Rome; Ceglie Messapica, Italy*)

Expression of Breast Cancer Metastasis Suppressor 1, BRMS-1, in Human Breast Cancer and the Biological Impact of BRMS-1 on the Migration of Breast Cancer Cells. Y. ZHANG, L. YE, Y. TAN, P. SUN, K. JI, W.G. JIANG (*Cardiff, UK; Jinan; Zibo; Shandong, China*)

Nuclear Survivin Expression in Stromal Cells of Phyllodes Tumors and Fibroadenomas of the Breast. H. HIRANO, K. MATSUSHITA, A. OKIMURA, T. YOSHIDA, T. KIZAKI, T. ITO (*Toyonaka, Osaka; Kawanishi; Sanda, Hyogo*)

Therapeutic Activity of Testosterone in Metastatic Breast Cancer. C. BONI, M. PAGANO, M. PANEBIANCO, A. BOLOGNA, N.M. ASENSIO, R. GNONI, D. FORMISANO, G. BISAGNI (*Reggio Emilia, Italy*)

Bisphosphonate-related Atypical Femoral Fracture with Bone Metastasis of Breast Cancer: Case Report and Review. K. HAYASHI, M. AONO, K. SHINTANI, K. KAZUKI (*Osaka, Japan*)

Glycodelin A –A Famous Lipocalin and Its Role in Breast Cancer. A.C. KÖLBL, U. JESCHKE, D. DIAN, K. FRIESE, U. ANDERGASSEN (*Munich, Germany*)

Experiences of Breast Cancer Survivors Participating in a Tailored Exercise Intervention –A Qualitative Study. M.-L. LUOMA, L. HAKAMIES-BLOMQVIST, C. BLOMQVIST, R. NIKANDER, M. GUSTAVSSON-LILIUS, T. SAARTO (*Helsinki; Tampere, Finland*)

Surgery for Breast Cancer Liver Metastases – Factors Determining Results. V. TRESKA, M. CERNA, V. LISKA, I. TRESKOVA, A. NARSANSKA, J. BRUHA (*Pilsen, Czech Republic*)

Propofol and Bupivacaine in Breast Cancer Cell Function *In Vitro* – Role of the NET1 Gene. P. ECIMOVIC, D. MURRAY, P. DORAN, D.J. BUGGY (*Dublin, Ireland*)

Plasma Free Serotonin as a Marker for Early Detection of Breast Cancer Recurrence. A. FRÖBE, L. ČICIN-ŠAIN, G. JONES, Ž. SOLDIĆ, J. LUKAČ, A. BOLANČA, Z. KUSIĆ (*Zagreb, Croatia; Mississauga, ON, Canada*)

Human Epidermal Growth Factor Receptor 2 Positivity Predicts Locoregional Recurrence in Patients with T1-T2 Breast Cancer. G. AUSILI CEFARO, D. GENOVESI, M. TRIGNANI, M. DI NICOLA (*Chieti, Italy*)

Hypofractionated Breast Cancer Radiotherapy. Helical Tomotherapy in Supine Position or Classic 3D-conformal Radiotherapy in Prone Position: Which is Better? F. CAMMAROTA, F.M. GIUGLIANO, L. IADANZA, L. CUTILLO, M. MUTO, D. TOLEDO, V. RAVO, S. FALIVENE, P. MUTO (*Naples, Italy*)

Identification of Patients with Node-negative, Triple-negative Breast Cancer who Benefit from Adjuvant Cyclophosphamide, Methotrexate and 5-Fluorouracil Chemotherapy. C.-E. WU, S.-C. CHEN, Y.-C. LIN, Y.-F. LO, S. HSUEH, H.-K. CHANG (*Taoyuan, Taiwan, ROC*)

In Vitro and *In Vivo* Efficacy of Novel Quinuclidinone Derivative Against Breast Cancer. A. MALKI, E.S. EL ASHRY (*Doha, Qatar; Alexandria, Egypt*)

Contribution of Emotional Distance and Reserve in Patient–Physician Communication in Healthy Study Patients and in Patients with Benign Breast Disease and Breast Cancer: A Prospective Case–Control Study in Finland. M. ESKELINEN, P. OLLONEN (*Kuopio, Finland*)

Kiss-1/GPR54 Protein Expression in Breast Cancer. E. PAPAICONOMOU, M. LYMPERI, C. PETRAKI, A. PHILIPPOU, P. MSAOUEL, F. MICHALOPOULOU, G. KAFIRI, G. VASSILAKOS, G. ZOGRAFOS, M. KOUTSILIERIS (*Athens, Greece*)

An Evaluation of Fatty Acid-CoA Ligase 4 in Breast Cancer. C.-H. TSAI, S.-M. SHEEN-CHEN, C.-Y. HUANG, Y.-J. CHEN, S.-Y. CHI, S.-F. KO, Y.-W. LEE, J.-L. LIANG, H.-W. HSU, E.-Y. HUANG, H.-C. CHEN, C.-C. HUANG, K.-M. RAU, R.-P. TANG (*Kaohsiung; Taoyuan, Taiwan, ROC*)

Overexpression of Androgen Receptor and Forkhead-box A1 Protein in Apocrine Breast Carcinoma. M. SASAHARA, A. MATSUI, Y. ICHIMURA, Y. HIRAKATA, Y. MURATA, E. MARUI (*Tokyo, Japan*)

Correlation of Wilms' Tumor 1 Isoforms with HER2 and ER- α and its Oncogenic Role in Breast Cancer. T. NASOMYON, S. SAMPHAO, S. SANGKHATHAT, S. MAHATTANOBON, P. GRAIDIST (*Songkhla, Thailand*)

Low Protein Expression of MET in ER- and HER2-positive Breast Cancer. F. ZAGOURI, A. BRANDSTETTER, D. MOUSSOLIS, D. CHRYSIKOS, C. DIMITRAKAKIS, A. TSIGGINOU, S. MARINOPOULOS, E. ZOGRAFOS, T.N. SERGENTANIS, M.-A. DIMOPOULOS, M. FILIPITS (*Vienna, Austria; Athens, Greece*)

Predictive and Prognostic Significance of Tumor-infiltrating Lymphocytes in Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy. B. MELICHAR, H. ŠTUDENTOVÁ, H. KALÁBOVÁ, D. VITÁSKOVÁ, P. ČERMÁKOVÁ, H. HORNYCHOVÁ, A. RYŠKA (*Olomouc; Králové, Czech Republic*)

CANCER GENOMICS & PROTEOMICS

www.cgp.iarjournals.org

Print ISSN (2004-2012): 1109-6535

Online ISSN: 1790-6245

VOL. 1 (2004) - VOL. 9 (2012) (print and online)
From VOL. 10 (2013) online – only and open access



International Online Open Access Journal

General Policy. CANCER GENOMICS & PROTEOMICS (CGP) welcomes submissions of original high quality articles and reviews on all aspects of the application of genomic and proteomic technologies to experimental and clinical cancer research. The journal's scientific spectrum includes: (a) molecular causes of carcinogenesis, cancer progression and metastasis; (b) structural and functional aspects of genes in the cancer cell; (c) advances in genomic and proteomic technologies applicable to cancer research; (d) anticancer drug design and drug development.

CGP will also accept abstracts and proceedings of scientific meetings for publication, following consideration and approval by the Editorial Board. A main aim of CGP is to ensure the prompt and confidential review, and rapid publication of original works and reviews, generally within 1-3 months from submission or 1-2 months from acceptance.

CGP is published bimonthly by the **International Institute of Anticancer Research** and is available online with **Stanford University HighWire Press**: For more information please visit our website www.cgp.iarjournals.org.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389. E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

A Selection of Recent Papers

Metastatic Biomarker Discovery Through Proteomics. L.T. BRINTON, T.A. BRETNALL, J.A. SMITH, K.A. KELLY (*Charlottesville, VA; Seattle, WA, USA*)

Genetically Engineered Fusion Proteins for Treatment of Cancer. U.H. WEIDLE, B. SCHNEIDER, G. GEORGES, U. BRINKMANN (*Penzberg, Germany*)

Identification of Differentially Expressed Proteins from Primary vs. Metastatic Pancreatic Cancer Cells Using Subcellular Proteomics. K.Q. MCKINNEY, J.-G. LEE, D. SINDRAM, M.W. RUSSO, D.K. HAN, H.L. BONKOVSKY, S.-I. HWANG (*Charlotte, NC; Farmington, CT, USA*)

Review: Are we Missing the Target? – Cancer Stem Cells and Drug Resistance in Non-small Cell Lung Cancer. S. GOTTSCHLING, P.A. SCHNABEL, F.J.F. HERTH, E. HERPEL (*Heidelberg, Germany*)

Identification of Markers Associated with Highly Aggressive Metastatic Phenotypes Using Quantitative Comparative Proteomics. M.G. TERP, R.R. LUND, O.N. JENSEN, R. LETH-LARSEN, H.J. DITZEL (*Odense, Denmark*)

Review: Breast Cancer and Metastasis: On the Way Toward Individualized Therapy. A.P. TRAPÉ, A.M. GONZALEZ-ANGULO (*Houston, TX, USA*)

In Silico Functional Profiling of Individual Prostate Cancer Tumors: Many Genes, Few Functions. I.P. GORLOV, J. BYUN, C.J. LOGOTHETIS (*Houston, TX, USA*)

Expression of Signal-induced Proliferation-associated Gene 1 (SIPA1), a RapGTPase-activating Protein, Is Increased in Colorectal Cancer and Has Diverse Effects on Functions of Colorectal Cancer Cells. K. JI, L. YE, A.-M. TOMS, R. HARGEST, T.A. MARTIN, F. RUGE, J. JI, W.G. JIANG (*Cardiff, UK; Beijing, PR China*)

Single Nucleotide Polymorphisms of Genes for EGF, TGF- β and TNF- α in Patients with Pancreatic Carcinoma. L. ZHANG, G. WU, F. HERRLE, M. NIEDERGETHMANN, M. KEESE (*Frankfurt; Heidelberg, Germany; Xiamen, P.R. China*)

Diagnostic MicroRNA Markers to Screen for Sporadic Human Colon Cancer in Blood. F.E. AHMED, N.C. AMED, P.W. VOS, C. BONNERUP, J.N. ATKINS, M. CASEY, G.J. NUOVO, W. NAZIRI, J.E. WILEY, R.R. ALLISON (*Greenville, Goldsboro, NC; Columbus, OH, USA*)

MGMT Hypermethylation and MDR System in Glioblastoma Cancer Stem Cells. V. CALDERA, M. MELLAI, L. ANNOVAZZI, O. MONZEGLIO, A. PIAZZI, D. SCHIFFER (*Pavia; Novara, Italy*)

20-HETE-producing Enzymes Are Up-regulated in Human Cancers. A. ALEXANIAN, B. MILLER, R.J. ROMAN, A. SOROKIN (*Milwaukee, WI; Jackson, MS, USA*)

Unifying the Genomics-based Classes of Cancer Fusion Gene Partners: Large Cancer Fusion Genes are Evolutionarily Conserved. L.M. PAVA, D.T. MORTON, R. CHEN, G. BLANCK (*Tampa, FL, USA*)

Instructions to Authors 2014

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):

1. To submit your article online please visit: IIAR-Submissions (<http://www.iiar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:

John G. Delinasios
 International Institute of Anticancer Research (IIAR)
 Editorial Office of ANTICANCER RESEARCH,
 IN VIVO, CANCER GENOMICS and PROTEOMICS.
 1st km Kapandritiou-Kalamou Road
 P.O. Box 22, GR-19014 Kapandriti, Attiki
 GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online with Stanford University HighWire Press

ISSN (print): 0258-851X; ISSN (online): 1791-7549

General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.
- One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.
- IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iv.iiarjournals.org

Selection of Recent Articles

Proteomic Profiling to Identify Prognostic Biomarkers in Heart Failure. P.A. SCOTT, B. ZEIDAN, L.L. NG, M. ZEB, J.A. ROSENGARTEN, S. GARBIS, N.P. CURZEN, J.M. MORGAN, P.A. TOWNSEND (*Southampton; Leicester, UK; Athens, Greece*)

Diverging *In Vitro* Antibody Isotype Switching Preference in B-Lymphocytes from C57BL/6 and FVB Mice. A.G. PUTHIYAVEETIL, B. OKYERE, C.M. REILLY, D. CAUDELL (*Blacksburg, VA, USA*)

The Zebrafish- *Danio rerio* – Is a Useful Model for Measuring the Effects of Small-molecule Mitigators of Late Effects of Ionizing Irradiation. M.W. EPPERLY, N. BAHARY, M. QUADER, V. DEWALD, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Breast Cancer: Mechanisms Involved in Action of Phytoestrogens and Epigenetic Changes. A. DAGDEMIR, J. DURIF, M. NGOLLO, Y.-J. BIGNON, D. BERNARD-GALLON (*Clermont-Ferrand, France*)

Positron-emission Tomography (PET) Imaging Agents for Diagnosis of Human Prostate Cancer: Agonist vs. Antagonist Ligands. P.K. NANDA, B.E. WIENHOFF, T.L. ROLD, G.L. SIECKMAN, A.F. SZCZODROSKI, T.J. HOFFMAN, B.E. ROGERS, C.J. SMITH (*Columbia; St. Louis, MO, USA*)

In Vivo Models for Defining Molecular Subtypes of the Primitive Neuroectodermal Tumor Genome: Current Challenges and Solutions. J.D. LARSON, D.A. LARGAESPADA (*Minneapolis, MN, USA*)

Effects of Minocycline on Hematopoietic Recovery After Whole-body Irradiation. S. MEHROTRA, M.J. PECAUT, D.S. GRIDLEY (*Loma Linda, CA, USA*)

Sequential Changes in the Expression of Wnt- and Notch-related Genes in the Vagina and Uterus of Ovariectomized Mice after Estrogen Exposure. T. NAKAMURA, S. MIYAGAWA, Y. KATSU, T. SATO, T. IGUCHI, Y. OHTA (*Yamagata; Okazaki; Sapporo; Yokohama; Tottori, Japan*)

Catecholamines Reduce Dose-dependent Oedema Formation and Inflammatory Reaction in an Isolated Rat Lung Model. C. DACHO, A. DACHO, A. GEISSLER, C. HAUSER, K. NOWAK, G. BECK (*Heidelberg; Essen; Wiesbaden, Germany*)

Biocompatibility of Membranes with Unrestricted Somatic Stem Cells. C. NAUJOKS, F.P. VON BECK, F. LANGENBACH, M. HENTSCHEL, K. BERR, M. HOFER, R. DEPFRICH, N. KÜBLER, J. HANDSCHEL (*Düsseldorf, Germany*)

Evaluation of Aortic Valve Stenosis Using a Hybrid Approach of Doppler Echocardiography and Inert Gas Rebreathing. K. HAMM, F. TRINKMANN, F. HEGGEMANN, J. GRUETTNER, G. SCHMID-BINDERT, M. BORGGREFE, D. HAGHI, J. SAUR (*Mannheim, Germany*)

Acclimatization of Mice to Different Cage Types and Social Groupings with Respect to Fecal Secretion of IgA and Corticosterone Metabolites. C.J. BUNDGAARD, O. KALLIOKOSKI, K.S. ABELSON, J. HAU (*Copenhagen, Denmark*)

Exploring Anticarcinogenic Agents in a Rat Hepatocarcinogenesis Model – Focus on Selenium and Statins. L. BJÖRKHEM-BERGMAN, L. EKSTRÖM, L.C. ERIKSSON (*Stockholm, Sweden*)

Amentoflavone Induces Cell-cycle Arrest and Apoptosis in MCF-7 Human Breast Cancer Cells via Mitochondria-dependent Pathway. J.-S. PEI, C.-C. LIU, Y.-N. HSU, L.-L. LIN, S.-C. WANG, J.-G. CHUNG, D.-T. BAU, S.-S. LIN (*TaoYuan; Taichung, Taiwan, ROC*)

Amino Acid Chloramine Damage to Proliferating Cell Nuclear Antigen in Mammalian Cells. S.A. SALAMA, R.M. SNAPKA (*Columbus, OH, USA; Cairo, Egypt*)

The Effect of Insulin-like Growth Factor II in the Regulation of Tumour Cell Growth *In Vitro* and Tumourigenesis *In Vivo*. M. HALJE, M. NORDIN, D. BERGMAN, W. ENGSTRÖM (*Uppsala, Sweden*)

FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST

Subscription Order Form 2014

- Please enter a Subscription to ANTICANCER RESEARCH Volume 34 (2014).
Annual subscription rates (2013): Institutional, Euro 1,650.00 print or online; Personal, Euro 780.00 print or online;
Prices include rapid delivery and insurance.
2014 online subscriptions include free online access to vol. 24 (2004) - 33 (2013).
- Please send me the following previous volumes (1-33) at 50% discount on the above rates.
- Payment is enclosed. Please invoice.
Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece)
- Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address:

 Tel:
 Fax: e-mail:
 Signature:..... Date:.....

Please send this order to ANTICANCER RESEARCH, Editorial Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org

Special 2014 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2014 on a basis of priority and availability. Effective from January to December 2014).

- **Included in Pubmed, Current Contents and all abstracting and indexing services**
- **Online with Stanford University HighWire Press**
- **Open access articles**



Your link to the essential information on cancer research published in the last 33 years.

- 1981-2013
- 33 volumes
- over 108,100 pages
- over 16,000 original articles
- 769 reviews
- over 73,300 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

Please complete and send this order form to:
 ANTICANCER RESEARCH, International Institute of Anticancer Research,
 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.

Special Subscription Order Form 2014

- I am one of the authors of the article published in Anticancer Research Vol....., pp., year
- Please enter my personal subscription to Anticancer Research 2014 (Volume 34) at the special Author's rate of Euro 390.00 (print or online).
- Please send me previous Volume No(s) at Euro 195.00 (print) per volume.
- Please enter my personal combined 2014 subscription to Anticancer Research (Volume 34) and IN VIVO (Volume 28) at Euro 560.00 (print or online).
- My payment is enclosed.
- Please send me an invoice.
Prices include rapid delivery and insurance. Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece).

Name and address:

 Tel-Fax:
 e-mail:
 Date and signature:

The Role of Lymphadenectomy in Uterine Sarcoma: A Clinical Practical Approach Based on Retrospective Analysis. F. HOELLEN, A. WALDMANN, S. BENTHIN, L. HANKER, A. RODY, D. FISCHER (<i>Luebeck, Germany</i>).....	985
The Role of Activation-induced Cytidine Deaminase Expression in Gastric Adenocarcinoma. B.-E. BATSAIKHAN, N. KURITA, T. IWATA, H. SATO, K. YOSHIKAWA, C. TAKASU, H. KASHIHARA, N. MATSUMOTO, H. ISHIBASHI, M. SHIMADA (<i>Tokushima, Japan</i>)	995
A Long-term Follow-up Study of 91 Cases with Ovarian Granulosa Cell Tumors. S.-H. SHIM, S.J. LEE, D.-Y. KIM, J. KIM, S.-N. KIM, S.-B. KANG, J.-H. KIM, Y.-M. KIM, Y.-T. KIM, J.-H. NAM (<i>Seoul, Republic of Korea</i>)	1001
Management of Painful Bone Metastases: Our Experience According to Scientific Evidence on Palliative Radiotherapy. R. DI FRANCO, S. FALIVENE, V. RAVO, M. MAMMUCARI, E. SARLI, S. BAFFINI, G. DE PALMA, A. PEPE, M. TRAETTINO, M. MUTO, S. CAPPABIANCA, P. MUTO (<i>Naples; Rome; Florence, Italy</i>).....	1011
Active Anticancer Treatment During the Final Month of Life in Patients with Non-small Cell Lung Cancer. C. NIEDER, T. TOLLÅLI, A. DALHAUG, E. HAUKLAND, G. AANDAHL, A. PAWINSKI, J. NORUM (<i>Bodø; Tromsø, Norway</i>)	1015
Prevalence and Expression of Human Papillomavirus in 53 Patients with Oral Tongue Squamous Cell Carcinoma. E. TSIMPLAKI, E. ARGYRI, D. XESFYNGI, D. DASKALOPOULOU, D.J. STRAVOPODIS, E. PANOTOPOULOU (<i>Athens, Greece</i>)	1021
Treatment of Collecting Duct Carcinoma: Current Status and Future Perspectives. G. PROCOPIO, I. TESTA, R. IACOVELLI, P. GRASSI, E. VERZONI, E. GARANZINI, M. COLECCHIA, T. TORELLI, F. DE BRAUD (<i>Milan, Italy</i>)	1027
Does a Venous Tumor Thrombus Exclude Renal Transitional Cell Carcinoma? Implications for Neo-Adjuvant Treatment Strategies. J. HUBER, D. TEBER, G. HATIBOGLU, V. POPENECIU, H. JAKOBI, P. HALLSCHEIDT, S. PAHERNIK, M. HOHENFELLNER (<i>Heidelberg, Germany</i>)	1031
Prognostic Factor Analysis in Core-Binding Factor-positive Acute Myeloid Leukemia. H.A. JUNG, C.H. MAENG, S. PARK, S.J. KIM, K. KIM, J.H. JANG, C.W. JUNG (<i>Seoul, Republic of Korea</i>)	1037
Clinical Characteristics of Advanced Hepatocellular Carcinoma Patients with Prolonged Survival in the Era of Anti-angiogenic Targeted-therapy. L.-C. LU, Y.-Y. SHAO, S.-Y. CHAN, C.-H. HSU, A.-L. CHENG (<i>Taipei; Yunlin, Taiwan, ROC</i>)	1047
The Feasibility of a Short Bevacizumab Infusion in Patients with Metastatic Colorectal Cancer. T. TERAZAWA, H. NISHITANI, K. KATO, H. HASHIMOTO, K. AKIYOSHI, S. IWASA, T.E. NAKAJIMA, T. HAMAGUCHI, Y. YAMADA, Y. SHIMADA (<i>Tokyo; Takatuki, Osaka; Kawasaki, Kanagawa, Japan</i>)...	1053
Large Synovial Osteochondromatosis Arising from the Interphalangeal Joint of the Thumb: A Case Report and Review of the Literature. K. MURAMATSU, T. HASHIMOTO, Y. TOMINAGA, T. TAGUCHI (<i>Ube, Yamaguchi, Japan</i>).....	1057
Errata	1061
Book Reviews	1063
Announcements	1069

L-[3- ¹⁸ F]- α -Methyltyrosine Accumulation as a Definitive Chemoradiotherapy Response Predictor in Patients with Esophageal Cancer. M. SOHDA, H. HONJYO, K. HARA, D. OZAWA, S. SUZUKI, N. TANAKA, A. SANO, M. SAKAI, T. YOKOBORI, T. INOSE, T. MIYAZAKI, H. OJIMA, T. HIGUCHI, Y. TSUSHIMA, H. KUWANO (<i>Maebashi, Gunma, Japan</i>).....	909
Is Gastric Tube Reconstruction the Optimal Surgical Procedure for Siewert Type II Esophagogastric Junction Carcinoma? M. FUKUCHI, E. MOCHIKI, O. SUZUKI, T. ISHIGURO, J. SOBAJIMA, K. SAITO, H. NAITOH, Y. KUMAGAI, H. BABA, K. ISHIBASHI, H. ISHIDA (<i>Saitama; Maebashi, Gunma, Japan</i>)....	915
External Validation of TNM-C Score in Three Community Hospital Cohorts for Clear Cell Renal Cell Carcinoma. T. NAKAYAMA, K. SAITO, J. ISHIOKA, K. KAWANO, S. MORIMOTO, Y. MATSUOKA, T. OKUNO, S. MORIYAMA, H. TAKESHITA, A. NORO, Y. FUJII, K. KIHARA (<i>Tokyo; Tsuchiura; Toride; Saitama, Japan</i>)	921
Split-dose Cisplatin and Vinorelbine as Adjuvant Chemotherapy for Completely Resected Non-small Cell Lung Cancer. F. HIRAI, T. SETO, M. SHIMOKAWA, E. INAMASU, R. TOYOZAWA, G. TOYOKAWA, T. YOSHIDA, Y. SHIRAIISHI, T. TAKENAKA, M. YAMAGUCHI, M. TAKENOYAMA, Y. ICHINOSE (<i>Fukuoka, Japan</i>).....	927
Role of High-sensitivity C-reactive Protein in the Differentiation of Benign and Malignant Soft Tissue Tumors. T. NAKAMURA, A. MATSUMINE, T. IINO, T. MATSUBARA, K. ASANUMA, A. UCHIDA, A. SUDO (<i>Tsu, Mie, Japan</i>)	933
PSA Nadir and Outcome in 100 Patients with pT3b Prostate Cancer. P. PEPE, G. IMPROTA, F. FRAGGETTA, C. EMMANUELE, V. SIMEON, G. DIBENEDETTO, M. COLECCHIA, F. ARAGONA (<i>Catania; Rionero in Vulture; Milan, Italy</i>)	937
User Rate of Complementary and Alternative Medicine (CAM) of Patients Visiting a Counseling Facility for CAM of a German Comprehensive Cancer Center. J. HUEBNER, O. MICKE, R. MUECKE, J. BUENTZEL, F.J. PROTT, U. KLEEBERG, B. SENF, K. MUENSTEDT, ON BEHALF OF PRIO (WORKING GROUP PREVENTION AND INTEGRATIVE ONCOLOGY OF THE GERMAN CANCER SOCIETY) (<i>Frankfurt; Bielefeld; Lemgo; Nordhausen; Wiesbaden; Hamburg; Gießen, Germany</i>)	943
Efficacy and Toxicity of Bevacizumab on Combination with Chemotherapy in Different Lines of Treatment for Metastatic Colorectal Carcinoma. I. KISS, Z. BORTLICEK, B. MELICHAR, A. POPRACH, J. HALAMKOVA, R. VYZULA, L. DUSEK, T. BUCHLER (<i>Brno; Olomouc; Prague, Czech Republic</i>).....	949
High UBCH10 Protein Expression as a Marker of Poor Prognosis in Esophageal Squamous Cell Carcinoma. A. MATSUMOTO, Y. ISHIBASHI, M. URASHIMA, N. OMURA, K. NAKADA, K. NISHIKAWA, A. SHIDA, K. TAKADA, H. KASHIWAGI, K. YANAGA (<i>Tokyo, Japan</i>).....	955
Symptomatic Intraosseous Lipoma in the Calcaneus. K. MURAMATSU, Y. TOMINAGA, T. HASHIMOTO, T. TAGUCHI (<i>Ube, Yamaguchi, Japan</i>)	963
Electrochemotherapy and Its Controversial Results in Patients with Head and Neck Cancer. V. SECCIA, L. MUSCATELLO, I. DALLAN, A. BAJRAKTARI, T. BRIGANTI, S. URSINO, L. GALLI, A. FALCONE, S. SELLARI-FRANCESCHINI (<i>Pisa, Italy</i>)	967
Metabolic Treatment of Cancer: Intermediate Results of a Prospective Case Series. L. SCHWARTZ, L. BUHLER, P. ICARD, H. LINCET, J.-M. STEYAERT (<i>Palaiseau; Paris; Lille; Côte de Nacre; Caen, France</i>)	973
Postoperative Bleeding After Surgery in Patients with Lung Cancer. H. URAMOTO, H. SHIMOKAWA, F. TANAKA (<i>Kitakyushu, Japan</i>)	981

Activation of <i>YAP1</i> Is Associated with Poor Prognosis and Response to Taxanes in Ovarian Cancer. W. JEONG, S.-B. KIM, B.H. SOHN, Y.-Y. PARK, E.S. PARK, S.C. KIM, S.S. KIM, R.L. JOHNSON, M. BIRRER, D.S.L. BOWTELL, G.B. MILLS, A. SOOD, J-S. LEE (<i>Seoul, Republic of Korea; Houston, TX; Boston, MA, USA; Melbourne, VIC, Australia</i>)	811
A Case Report of an Ependyoblastoma in the Rectovaginal Space and a Review of the Literature. E. SMOLLE, M. SMOLLE, F. RONAGHI, H. ROGATSCH, F. MOINFAR, J. HAYBAECK (<i>Graz; St. Veit/Glan; Klagenfurt/Wörthersee, Austria</i>)	819
Health Utilities in Gynecological Oncology and Mastology in Germany. T. HILDEBRANDT, F.C. THIEL, P.A. FASCHING, C. GRAF, M.R. BANI, C.R. LOEHLBERG, M.G. SCHRAUDER, S.M. JUD, C.C. HACK, M.W. BECKMANN, M.P. LUX (<i>Erlangen, Germany</i>)	829
Late Oral Mucosa Alterations After Radiotherapy for Head and Neck Cancer Assessed by Exfoliative Cytology. P. MASSARO, F. CORBELLA, R. DI LIBERTO, A. PAOLINI, F. PASI, C. TINELLI, A. DE SILVESTRI, R. NANO (<i>Pavia, Italy</i>)	837
Gemcitabine and Capecitabine for Heavily Pre-treated Metastatic Colorectal Cancer Patients – A Phase II and Translational Research Study. K.-L. G. SPINDLER, N. PALLISGAARD, R.F. ANDERSEN, J. PLOEN, A. JAKOBSEN (<i>Vejle, Denmark</i>)	845
Randomized Phase II Trial of S-1 plus Irinotecan <i>Versus</i> S-1 plus Paclitaxel as First-line Treatment for Advanced Gastric Cancer (OGSG0402). N. SUGIMOTO, K. FUJITANI, H. IMAMURA, N. UEDO, S. IJIMA, M. IMANO, T. SHIMOKAWA, Y. KUROKAWA, H. FURUKAWA, M. GOTO (<i>Osaka; Yamanashi, Japan</i>)	851
Aldehyde Dehydrogenase-1 Predicts Favorable Prognosis in Patients with Vulvar Squamous Cell Carcinoma. Q. WU, H. SHI, R. HOLM, X. LI, C. TROPE, J.M. NESLAND, Z. SUO (<i>Zhengzhou, China; Oslo, Norway</i>) ...	859
HER2-positive Gastric Cancer with Paraaortic Nodal Metastasis Successfully Resected After Chemotherapy with Trastuzumab: A Case Report. N. IKARI, G. NAKAJIMA, K. TANIGUCHI, T. SASAGAWA, K. NARUMIYA, T. YAMADA, K. KUDO, Y. KITAMURA, K. HAYASHI, T. NISHIKAWA, M. YAMAMOTO (<i>Tokyo, Japan</i>)	867
Treatment of Periocular Basal Cell Carcinoma Using an Advanced Stereotactic Device. A. PONTORIERO, G. IATÌ, A. CONTI, F. MINUTOLI, A. BOTTARI, S. PERGOLIZZI, C. DE RENZIS (<i>Messina, Italy</i>)....	873
Development and Validation of a Model Predicting Short Survival (Death Within 30 Days) After Palliative Radiotherapy. K. ANGELO, J. NORUM, A. DALHAUG, A. PAWINSKI, G. AANDAHL, E. HAUKLAND, K. ENGLJÄHRINGER, C. NIEDER (<i>Tromsø; Bodø, Norway</i>)	877
Tumor Marker Score for Prognostication of Early-stage Squamous Cell Cervical Cancer. D. HELLBERG, T. TOT (<i>Uppsala; Falun, Sweden</i>)	887
Molecular Typing of Human Herpesvirus 8 Isolates from Patients with Kaposi's Sarcoma in Hungary. R. ÖTVÖS, A. JUHASZ, E. SZALAI, D. UJVARI, K. ÖTVÖS, K. SZABO, E. REMENYIK, L. SZEKELY, L. GERGELY, J. KONYA (<i>Debrecen; Kaposvár; Budapest, Hungary; Stockholm, Sweden</i>)	893
Successful Resection of Esophageal Carcinoma with Aberrant Right Subclavian Artery Using Video-assisted Thoracoscopic Surgery: Report of Two Cases. H. KASASHIMA, N. KUBO, M. OHIRA, K. SAKURAI, T. TOYOKAWA, H. TANAKA, K. MUGURUMA, M. SHIBUTANI, S. YAMAZOE, K. KIMURA, H. NAGAHARA, R. AMANO, H. OHTANI, M. YASHIRO, K. MAEDA, K. HIRAKAWA (<i>Osaka, Japan</i>)....	899
Complete Pathological Response in Advanced Extra-gastrointestinal Stromal Tumor After Imatinib Mesylate Therapy: A Case Report. M. REDITI, E. PELLEGRINI, E. MOLINARA, C. CERULLO, C. FONTE, A. LUNGI, A. IORI, B. NERI (<i>Florence, Italy</i>)	905

Vascular Endothelial Growth Inhibitor 174 Is a Negative Regulator of Aggressiveness and Microvascular Density in Human Clear Cell Renal Cell Carcinoma. L. WU, X. LI, L. YE, D. SHAYIREMU, X. DENG, X. ZHANG, W. JIANG, Y. YANG, K. GONG, N. ZHANG (<i>Beijing; Hami; Karamay, Xinjiang Uygur Autonomous Region, PR China; Cardiff, UK</i>)	715
ESR1 Promoter Methylation in Squamous Cell Cervical Cancer. V. KIRN, I. ZAHARIEVA, S. HEUBLEIN, F. THANGARAJAH, K. FRIESE, D. MAYR, U. JESCHKE (<i>Cologne; Munich, Germany</i>)	723
TRAIL-engineered Bone Marrow-derived Mesenchymal Stem Cells: TRAIL Expression and Cytotoxic Effects on C6 Glioma Cells. X.-J. TANG, J.-T. LU, H.-J. TU, K.-M. HUANG, R. FU, G. CAO, M. HUANG, L.-H. CHENG, L.-J. DAI, L. ZHANG (<i>Shiyan; Hubei, PR China; Vancouver, BC, Canada</i>)	729
Patient-derived Sialyl-Tn-positive Invasive Bladder Cancer Xenografts in Nude Mice: An Exploratory Model Study. C. BERNARDO, C. COSTA, T. AMARO, M. GONÇALVES, P. LOPES, R. FREITAS, F. GÄRTNER, F. AMADO, J.A. FERREIRA, L. SANTOS (<i>Porto; Matosinhos; Aveiro, Portugal</i>)	735
Distinct Expression and Localization of TNF System in Ovarian Carcinoma Tissues: Possible Involvement of TNF- α in Morphological Changes of Ovarian Cancerous Cells. B. PIURA, L. MEDINA, A. RABINOVICH, V. DYOMIN, R.S. LEVY, M. HULEIHEL (<i>Beer-Sheva, Israel</i>)	745
The Significance of <i>HSP90AA1</i> , <i>HSP90AB1</i> and <i>HSP90B1</i> Gene Polymorphisms in a Turkish Population with Non-small Cell Lung Cancer. E. COSKUNPINAR, N. AKKAYA, P. YILDIZ, Y.M. OLTULU, E. AYNACI, T. ISBIR, I. YAYLIM (<i>Istanbul, Turkey</i>)	753
3'-Deoxy-3'-[¹⁸ F]Fluorothymidine Positron Emission Tomography Imaging of Thymidine Kinase 1 Activity After 5-Fluorouracil Treatment in a Mouse Tumor Model. I.K. HONG, S.Y. KIM, J.H. CHUNG, S.J. LEE, S.J. OH, S.J. LEE, J. OH, J.-S. RYU, T.W. KIM, D.Y. KIM, D.H. MOON (<i>Seoul; Incheon, Republic of Korea</i>)	759
<i>Clinical Studies</i>	
Factors Predictive of Survival After Stapler Hepatectomy of Hepatocellular Carcinoma: A Multivariate, Single-center Analysis. K. HOFFMANN, V. MÜLLER-BÜTOW, C. FRANZ, U. HINZ, T. LONGERICH, M.W. BÜCHLER, P. SCHEMMER (<i>Heidelberg, Germany</i>)	767
Diagnosis, Treatment and Survival of 65 Patients with Malignant Peripheral Nerve Sheath Tumors. O. GOERTZ, S. LANGER, D. UTHOFF, A. RING, I. STRICKER, A. TANNAPFEL, H.-U. STEINAU (<i>Bochum, Germany</i>)	777
Hodgkin's Variant of Richter Transformation in Chronic Lymphocytic Leukemia; A Retrospective Study from the Israeli CLL Study Group. T. TADMOR, L. SHVIDEL, N. GOLDSCHMIDT, R. RUCHLEMER, R. FINEMAN, O. BAIREY, N. RAHIMI-LEVENE, Y. HERISHANU, M. YUKLEA, A. ARAD, A. AVIV, A. POLLIACK (<i>Haifa; Rehovot; Jerusalem; Petah-Tikva; Zerifin; Kfar-Saba; Natanya; Afula, Israel</i>)	785
¹⁸ F-DOPA PET/CT and MRI: Description of 12 Histologicallyverified Pheochromocytomas. S. MAGNALDI, M.E. MAYERHOEFER, A. KHAMENEH, M. SCHUETZ, D. JAVOR, M. MITTERHAUSER, R. DUDCZAK, M. HACKER, G. KARANIKAS (<i>Vienna, Austria</i>)	791
Self-estimation or Phototest Measurement of Skin UV Sensitivity and its Association with People's Attitudes Towards Sun Exposure. M. FALK (<i>Linköping, Sweden</i>)	797
Use of Maximum Standardized Uptake Value on Fluorodeoxyglucose Positron-emission Tomography in Predicting Lymph Node Involvement in Patients with Primary Non-small Cell Lung Cancer. J. MUTO, Y. HIDA, K. KAGA, K. OHTAKA, S. OKAMOTO, N. TAMAKI, R. NAKADA-KUBOTA, S. HIRANO, Y. MATSUI (<i>Sapporo, Japan</i>)	805

Experimental Studies

Melting Curve Analysis for Mutations of <i>EGFR</i> and <i>KRAS</i> . K. FURUGAKI, H. YASUNO, T. IWAI, Y. MORIYA, N. HARADA, K. FUJIMOTO-OUCHI (<i>Kamakura, Kanagawa, Japan</i>).....	613
Expression of PDGFR- α , EGFR and c-MET in Spinal Chordoma: A Series of 52 Patients. R. AKHAVAN-SIGARI, M.R. GAAB, V. ROHDE, M. ABILI, H. OSTERTAG (<i>Göttingen; Hannover, Germany; Mashhad, Iran</i>)	623
Role of Autophagy in Apoptotic Regulation by Akt in Pancreatic Cancer. D. MUILENBURG, C. PARSONS, J. COATES, S. VIRUDACHALAM, R.J. BOLD (<i>Sacramento, CA, USA</i>)	631
DNA from Human Polyomaviruses, TSPyV, MWPyV, HPyV6, 7 and 9 Was Not Detected in Primary Mucosal Melanomas. T. RAMQVIST, C. NORDFORS, T. DALIANIS, B. RAGNARSSON-OLDING (<i>Stockholm, Sweden</i>)	639
Peptides Against Mac-1 Do Not Sufficiently Target Leukemia or Lymphoma <i>In Vivo</i> . J. SUOJANEN, J. REUNANEN, T.-M. RANTA, O. PEÑATE-MEDINA, T. SALO, P. SARIS, T. SORSA (<i>Helsinki; Oulu, Finland; Kiel, Germany</i>).....	645
The Prognostic Significance of Eukaryotic Elongation Factor 1 Alpha-2 in Non-small Cell Lung Cancer. M. KAWAMURA, C. ENDO, A. SAKURADA, F. HOSHI, H. NOTSUDA, T. KONDO (<i>Sendai, Miyagi, Japan</i>)	651
The Cytoplasmic Extension of the Integrin $\beta 6$ Subunit Regulates Epithelial-to-Mesenchymal Transition. C. LEE, C. LEE, S. LEE, A. SIU, D.M. RAMOS (<i>San Francisco, CA; San Antonio, TX, USA</i>).....	659
Serum microRNAs as Biomarkers in Patients Undergoing Prostate Biopsy: Results from a Prospective Multi-Center Study. A.M. WESTERMANN, D. SCHMIDT, S. HOLDENRIEDER, R. MORITZ, A. SEMJONOW, M. SCHMIDT, G. KRISTIANSEN, S.C. MÜLLER, J. ELLINGER (<i>Bonn; Muenster, Germany</i>)	665
Differential Expression of Vascular Endothelial Growth Factor in High- and Low-Metastasis Cell Lines of Salivary Gland Adenoid Cystic Carcinoma. S. KONDO, Y. MUKUDAI, D. SOGA, T. NISHIDA, M. TAKIGAWA, T. SHIROTA (<i>Tokyo; Okayama, Japan</i>)	671
Biomarkers for Predicting Complete Debulking in Ovarian Cancer: Lessons to Be Learned. C.L. FAGÖ-OLSEN, B. OTTESEN, I.J. CHRISTENSEN, E. HØGDALL, L. LUNDEVALL, L. NEDERGAARD, S.-A. ENGELHOLM, S.L. ANTONSEN, M. LYDOLPH, C. HØGDALL (<i>Copenhagen; Herlev, Denmark</i>).....	679
Chemoprevention by Lipid-soluble Tea Polyphenols in Diethylnitrosamine/Phenobarbital-induced Hepatic Pre-cancerous Lesions. T. SHEN, S.C. KHOR, F. ZHOU, T. DUAN, Y.-Y. XU, Y.-F. ZHENG, S. HSU, J. DE STEFANO, J. YANG, L.-H. XU, X.-Q. ZHU (<i>Hangzhou, Zhejiang; Shanghai, PR China; Augusta, GA, USA</i>)	683
Accumulation of FGF9 in Prostate Cancer Correlates with Epithelial-to-Mesenchymal Transition and Induction of VEGF-A Expression. J. TEISHIMA, S. YANO, K. SHOJI, T. HAYASHI, K. GOTO, H. KITANO, K. OKA, H. NAGAMATSU, A. MATSUBARA (<i>Hiroshima, Japan</i>)	695
Myricetin Induces Cell Death of Human Colon Cancer Cells <i>via</i> BAX/BCL2-Dependent Pathway. M.E. KIM, T.K. HA, J.H. YOON, J.S. LEE (<i>Gwangju; Busan, Republic of Korea</i>)	701
Assessment of Intratumoral Heterogeneity of Oncogenic Driver Mutations in Surgically-resected Lung Adenocarcinoma: Implications of Percutaneous Biopsy-based Molecular Assay for Target-directed Therapy. H.K. KIM, H.Y. LEE, Y.-L. CHOI, S.-J. CHOI, H. CHOI, J. LEE, J. HAN, M.-J. AHN, K.S. LEE, J. KIM (<i>Seoul, Republic of Korea</i>)	707